IZIDORE(S.(LOSSOS((MIAMI)(
(
WHAT(WE(CAN(LEARN(FROM(A(SINGLE(CASE(OF(ENMZL(WITH(MULTIPLE(
MUCOSAL(SITES(PRESENTATION?(
(
In! the! current! era,! oncology! is! focusing! on! treatment! and! improving! patients’! outcome.!
However,! clinical! features! at! presentation! can! predict! the! natural! history! of! the! ENMZL! in!
specific! patients! and! help! to! guide! therapy! and! predict! the! roadblocks! that! can! be!
encountered! during! the! follow>up.! A! case! of! a! 50>year>old! patient! presenting! with! ocular!
adnexa!and!nasal!presentation!associated!with!monoclonal!gammopathy!and!followed!up!for!
6!years!will!be!discussed.!The!discussion!will!focus!on!prognostic!factors!at!presentation!with!
discussion! of! MALT>IPI! in! comparison! to! IPI! and! FLIPI.! Specific! prognostic! factors! in! ocular!
adnexa! ENMZL! will! be! discussed.! The! clinical! and! prognostic! significance! of! monoclonal!
gammopathy! and! multiple! mucosal! site! presentation! will! be! discussed.! Implications! for!
choroid! presentation! during! the! natural! course! will! be! reviewed.! Risk! factors! for!
transformation! to! diffuse! large! B! cell! lymphoma! will! be! presented! and! treatment! of!
transformation! in! patients! with! MZL! will! be! reviewed.! The! attendants! will! learn! on! novel!
clinical!features!and!their!association!with!prognosis,!transformation!and!outcome.!
!
References:(
1. Alderuccio!JP,!Zhao!W,!Desai!A,!Ramdial!J,!Gallastegui!N,!Kimble!E,!de!la!Fuente!MI,!Husnain!
M,!Rosenblatt!JD,!Alencar!AJ,!Schatz!JH,!Moskowitz!CH,!Chapman!JR,!Vega!F,!Reis!IM,!Lossos!
IS.!Short!Survival!and!Frequent!Transformation!in!Extranodal!Marginal!Zone!Lymphoma!with!
Multiple!Mucosal!Sites!Presentation.!American!Journal!of!Hematology.!2019!May;94(5):585>
596.!Epub!2019!Mar!10.!
2. Alderuccio! JP,! Zhao! W,! Desai! A,! Gallastegui! N,! Ramdial! J,! Kimble! E,! de! la! Fuente! MI,!
Rosenblatt! JD,! Chapman! JR,! Vega! F,! Reis! IM,! Lossos! IS.! Risk! Factors! for! Transformation! to!
Higher>Grade! Lymphoma! and! Its! Impact! on! Survival! in! a! Large! Cohort! of! Patients! with!
Marginal! Zone! Lymphoma! From! a! Single! Institution.! Journal! of! Clinical! Oncology.! 2018;!
36:3370>3380.!Epub!ahead!of!print!2018!Oct!12.!
3. Desai!A,!Joag!MG,!Lekakis!L,!Chapman!JR,!Vega!F,!Tibshirani!R,!Tse!D,!Markoe!A,!Lossos!IS.!
Long>term! course! of! patients! with! primary! ocular! adnexal! MALT! lymphoma:! a! large! single>
institution!cohort!study.!Blood.(2017!Jan!19;129(3):324>332.!Epub!2016!Oct!27.!
4. Rosado!MF,!Byrne!GE!Jr,!Ding!F,!Fields!KA,!Ruiz!P,!Dubovy!SR,!Walker!GR,!Markoe!A,!Lossos!
IS.!Ocular!adnexal!lymphoma:!a!clinicopathologic!study!of!a!large!cohort!of!patients!with!no!
evidence!for!an!association!with!Chlamydia(psittaci.!Blood.!2006!Jan!15;107(2):467>72.!Epub!
2005!Sep!15!
(
( (
SCIENTIFIC PROGRAMME
SESSION I
HODGKIN’S DISEASE
DEBATE I
IS THERE STILL A ROLE
FOR COMBINED MODALITY
THERAPY FOR EARLY
STAGE CHL?
SESSION II
T-CELL LYMPHOMA
ROUNDTABLE I
FUTURE DIRECTIONS IN
T-CELL LYMPHOMA
SESSION III
FOLLICULAR LYMPHOMA
DEBATE II
CAN WE AVOID
CHEMOTHERAPY IN
THE MANAGEMENT OF
FOLLICULAR LYMPHOMA?
SESSION IV
RARE LYMPHOMAS –
MARGINAL ZONE
LYMPHOMA AND
WALDENSTRÖM M
ACROGLOBULINEMIA
ROUNDTABLE II – WHERE
TO GO IN RARE B-CELL
LYMPHOMAS
SESSION V
MANTLE CELL LYMPHOMA
SESSION VI
DIFFUSE LARGE B-CELL
LYMPHOMA
DEBATE III
DO WE STILL NEED ASCT
IN MCL?
SESSION VII
NOVEL THER APEUTIC
CONCEPTS IN B-CELL
LYMPHOMAS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
DISCLOSURES